MannKind rises after FDA approves inhaled insulin for children
29/05/2026 17:50
BUZZ-MannKind rises after FDA approves inhaled insulin for children ** Shares of drugmaker MannKind MNKD.O rise 5.1% to $3.82
** Co says the U.S. FDA approved expanded use of its inhaled insulin Afrezza for children and adolescents aged 6 and older with type 1 or type 2 diabetes
** Afrezza is taken through a small inhaler, offering patients under 18 years of age a needle-free treatment option
** Co says eligible patients can get access to Afrezza for $35 or less a month
** Including session's move, MNKD down 32.5% YTD
(Reporting by Kunal Das in Bengaluru)
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children